Erlotinib (Tarceva®): A promising drug targeting epidermal growth factor receptor tyrosine kinase

Anca M. Bulgaru, Sridhar Mani, Sanjay Goel, Roman Perez-Soler

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor prognosis in several human malignancies. In addition, cancers overexpressing EGFR respond poorly to both chemotherapy and radiation therapy. Therefore, EGFR is a viable target for cancer therapy. This review will address how EGFR blockade modulates signal transduction, leading to alterations in the cell cycle progression with secondary inhibition of proliferation and differentiation of cancer cells. As a prototypical example, erlotinib (Tarceva®), a reversible EGFR tyrosine kinase inhibitor will be discussed. This drug has demonstrated promising antitumor activity in Phase II trials in several solid tumors and definitive Phase III studies to demonstrate clinical benefit have completed accrual.

Original languageEnglish (US)
Pages (from-to)269-279
Number of pages11
JournalExpert Review of Anticancer Therapy
Issue number3
StatePublished - Jun 2003


  • EGFR
  • Erlotinib
  • Phosphorylation
  • Tarceva®
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Erlotinib (Tarceva®): A promising drug targeting epidermal growth factor receptor tyrosine kinase'. Together they form a unique fingerprint.

Cite this